Cybin Investor Relations Material

Cybin Inc. is a clinical-stage biopharmaceutical company dedicated to developing psychedelic-based therapeutics. The company focuses on creating treatments for mental health conditions through innovative drug discovery platforms, drug delivery systems, and formulation approaches. Cybin is developing a range of proprietary psychedelic molecules, including CYB003, a deuterated psilocybin analog for major depressive disorder, and CYB004, a deuterated DMT molecule for generalized anxiety disorder. These efforts are part of Cybin's broader mission to address unmet needs in mental healthcare with novel therapeutic options. The company is headquartered in Toronto, Canada, and its shares are listed on the NYSE.